CN117136055A - 包含诱导抗老化基因klotho的表达的化合物的用于预防或治疗退行性神经疾病的组合物 - Google Patents

包含诱导抗老化基因klotho的表达的化合物的用于预防或治疗退行性神经疾病的组合物 Download PDF

Info

Publication number
CN117136055A
CN117136055A CN202280026649.3A CN202280026649A CN117136055A CN 117136055 A CN117136055 A CN 117136055A CN 202280026649 A CN202280026649 A CN 202280026649A CN 117136055 A CN117136055 A CN 117136055A
Authority
CN
China
Prior art keywords
chemical formula
side chain
compound
oxazol
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280026649.3A
Other languages
English (en)
Chinese (zh)
Inventor
郑东柱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kloso Science
Original Assignee
Kloso Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kloso Science filed Critical Kloso Science
Publication of CN117136055A publication Critical patent/CN117136055A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN202280026649.3A 2021-04-01 2022-03-28 包含诱导抗老化基因klotho的表达的化合物的用于预防或治疗退行性神经疾病的组合物 Pending CN117136055A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2021-0042958 2021-04-01
KR20210042958 2021-04-01
KR10-2021-0130307 2021-09-30
KR1020210130307A KR102375097B1 (ko) 2021-04-01 2021-09-30 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물
PCT/KR2022/004341 WO2022211420A1 (ko) 2021-04-01 2022-03-28 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
CN117136055A true CN117136055A (zh) 2023-11-28

Family

ID=80936324

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280026649.3A Pending CN117136055A (zh) 2021-04-01 2022-03-28 包含诱导抗老化基因klotho的表达的化合物的用于预防或治疗退行性神经疾病的组合物

Country Status (9)

Country Link
US (1) US20240358683A1 (https=)
EP (1) EP4316487A4 (https=)
JP (1) JP7728031B2 (https=)
KR (1) KR102375097B1 (https=)
CN (1) CN117136055A (https=)
AU (1) AU2022251900B2 (https=)
BR (1) BR112023019984A2 (https=)
CA (1) CA3213904A1 (https=)
WO (1) WO2022211420A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102375097B1 (ko) * 2021-04-01 2022-03-17 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물
JP7728030B2 (ja) * 2021-04-01 2025-08-22 クロトー サイエンシーズ カンパニー リミテッド 抗老化遺伝子klothoの発現を誘導する化合物を含む慢性腎疾患の予防または治療用組成物
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088770A (en) * 1971-05-04 1978-05-09 Eli Lilly And Company Substituted 2-anilinobenzoxazoles used as immunosuppressive agents
US20070066577A1 (en) * 2003-04-03 2007-03-22 Hea Young Park Choo Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
KR20110137868A (ko) * 2010-06-18 2011-12-26 이화여자대학교 산학협력단 Interleukin―6 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
KR101446301B1 (ko) * 2013-04-11 2014-10-06 서울대학교산학협력단 Cxcr3/cxcl10 길항제 화합물, 이의 제조방법 및 이를 포함하는 골 전이의 예방 및 치료용 약학 조성물
KR20170024522A (ko) * 2015-08-24 2017-03-07 이화여자대학교 산학협력단 2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
CN114502541A (zh) * 2019-10-02 2022-05-13 克洛索科学公司 诱导抗老化基因klotho的表达的化合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713474B2 (en) * 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
EP1388341A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
JP2008506686A (ja) 2004-07-16 2008-03-06 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク ベータ−アミロイドペプチドの形成を阻害することによるアルツハイマー病治療用化合物及び製造
EP1910385B1 (en) * 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazoles and thiazolopyridines as sirtuin modulators
WO2010039186A2 (en) * 2008-09-23 2010-04-08 Renovis, Inc. Compounds useful as faah modulators and uses thereof
WO2010129954A1 (en) * 2009-05-08 2010-11-11 Apogee Biotechnology Corporation Treatment of ischemia-reperfusion injury
KR20160069736A (ko) * 2014-12-09 2016-06-17 (주)아모레퍼시픽 메틸화된 카테킨을 유효성분으로 함유하는 Klotho 유전자 활성화용 조성물
US10647689B2 (en) 2015-04-28 2020-05-12 Sanford Burnham Prebys Medical Discovery Institute Apelin receptor agonists and methods of use thereof
KR102064611B1 (ko) * 2017-10-13 2020-01-09 이화여자대학교 산학협력단 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
KR102522955B1 (ko) 2018-09-26 2023-04-19 미쓰비시 덴키 빌딩 솔루션즈 가부시키가이샤 엘리베이터 시스템 및 휴대 단말
KR102749973B1 (ko) 2020-04-21 2025-01-06 엘지마그나 이파워트레인 주식회사 전기모터 및 이를 구비한 전기차량
KR102375097B1 (ko) * 2021-04-01 2022-03-17 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088770A (en) * 1971-05-04 1978-05-09 Eli Lilly And Company Substituted 2-anilinobenzoxazoles used as immunosuppressive agents
US20070066577A1 (en) * 2003-04-03 2007-03-22 Hea Young Park Choo Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
KR20110137868A (ko) * 2010-06-18 2011-12-26 이화여자대학교 산학협력단 Interleukin―6 억제 작용을 갖는 신규한 벤즈옥사졸 유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
KR101446301B1 (ko) * 2013-04-11 2014-10-06 서울대학교산학협력단 Cxcr3/cxcl10 길항제 화합물, 이의 제조방법 및 이를 포함하는 골 전이의 예방 및 치료용 약학 조성물
KR20170024522A (ko) * 2015-08-24 2017-03-07 이화여자대학교 산학협력단 2-(페닐아미노)벤조[d]옥사졸-5-올 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 염증성 질환의 예방 또는 치료용 약학적 조성물
CN114502541A (zh) * 2019-10-02 2022-05-13 克洛索科学公司 诱导抗老化基因klotho的表达的化合物及其用途

Also Published As

Publication number Publication date
EP4316487A1 (en) 2024-02-07
CA3213904A1 (en) 2022-10-06
JP7728031B2 (ja) 2025-08-22
AU2022251900B2 (en) 2025-09-18
US20240358683A1 (en) 2024-10-31
EP4316487A4 (en) 2025-04-09
JP2024512818A (ja) 2024-03-19
AU2022251900A9 (en) 2023-11-09
AU2022251900A1 (en) 2023-10-26
WO2022211420A1 (ko) 2022-10-06
BR112023019984A2 (pt) 2024-04-02
KR102375097B1 (ko) 2022-03-17

Similar Documents

Publication Publication Date Title
JP7628591B2 (ja) 抗老化遺伝子klothoの発現を誘導する化合物およびその用途
CN117136055A (zh) 包含诱导抗老化基因klotho的表达的化合物的用于预防或治疗退行性神经疾病的组合物
CN102369202A (zh) 氮杂喹啉酮衍生物及其应用
JP2014528428A (ja) 代謝症及び関連障害の治療のためのモノアシルグリセロールリパーゼ阻害剤
CN117157280A (zh) 包含诱导抗老化基因klotho的表达的化合物的用于预防或治疗慢性肾脏疾病的组合物
KR102463786B1 (ko) 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 만성신장질환의 예방 또는 치료용 조성물
JP7803597B2 (ja) 抗老化遺伝子klothoの発現を誘導する新規化合物
EP4317140A1 (en) Composition for preventing or treating chronic kidney disease, comprising compound that induces expression of anti-aging gene klotho
EP4353710A1 (en) Novel indole derivative, and use thereof for treating diseases related to advanced glycation end products
KR20190114500A (ko) 에피갈로카테킨 갈레이트 프로드러그, 이의 제조방법 및 이를 포함하는 미토콘드리아 생합성 촉진용 조성물
JPH09124471A (ja) メイラード反応阻害剤
KR20230108008A (ko) 1-알킬-5-아릴리덴-2-셀레녹소이미다졸리딘-4-온 및 그 유도체를 포함하는 염증성 질환의 예방, 개선 또는 치료용 약학조성물 및 식품조성물
JP2010180160A (ja) 新規dif−1誘導体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination